## Francesco Morescalchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4096891/publications.pdf

Version: 2024-02-01

933447 1125743 14 450 10 13 citations h-index g-index papers 14 14 14 620 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Proliferative Vitreoretinopathy after Eye Injuries: An Overexpression of Growth Factors and Cytokines Leading to a Retinal Keloid. Mediators of Inflammation, 2013, 2013, 1-12.	3.0	107
2	<p>Central Serous Chorioretinopathy: Pathogenesis and Management</p> . Clinical Ophthalmology, 2019, Volume 13, 2341-2352.	1.8	57
3	Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Japanese Journal of Ophthalmology, 2012, 56, 608-612.	1.9	48
4	Controversies over the role of internal limiting membrane peeling during vitrectomy in macular hole surgery. Survey of Ophthalmology, 2017, 62, 58-69.	4.0	46
5	Heavy Silicone Oil and Intraocular Inflammation. BioMed Research International, 2014, 2014, 1-16.	1.9	44
6	Current Trends about Inner Limiting Membrane Peeling in Surgery for Epiretinal Membranes. Journal of Ophthalmology, 2015, 2015, 1-13.	1.3	39
7	Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1141-1148.	1.9	27
8	Comparative assessment of intraocular inflammation following standard or heavy silicone oil tamponade: a prospective study. Acta Ophthalmologica, 2019, 97, e97-e102.	1.1	27
9	Efficacy and vitreous levels of topical NSAIDs. Expert Opinion on Drug Delivery, 2015, 12, 1767-1782.	5.0	18
10	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Expert Opinion on Drug Safety, 2019, 18, 803-815.	2.4	13
11	COVID-19 AdenoviralVector Vaccine and Central Retinal Vein Occlusion. Ocular Immunology and Inflammation, 0, , 1-3.	1.8	13
12	From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety. Expert Opinion on Drug Safety, 2016, 15, 1267-1278.	2.4	6
13	Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial. Clinical Ophthalmology, 2018, Volume 12, 587-591.	1.8	4
14	Risk factors for postoperative eye pain in patients with non-painful eye disease undergoing pars plana vitrectomy: the VItrectomy Pain (VIP) study. Minerva Anestesiologica, 2021, 87, 541-548.	1.0	1